Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corp    EW

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Edwards Lifesciences Corp : Edwards Lifesciences' Chairman and CEO to Exercise Stock Options Under 10b5-1 Stock Trading Plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/01/2013 | 04:37pm CET

IRVINE, CA, March 01, 2013 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that its chairman and chief executive officer, Michael A. Mussallem, has adopted a pre-arranged stock trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934. In May 2013, the plan will begin exercising stock options, the vast majority of which are scheduled to expire in 2014.

The plan anticipates the exercise and sale of 29,500 shares per month at market prices between May 2013 and April 2014. Rule 10b5-1 allows corporate executives to adopt stock trading plans to buy or sell shares of company stock when they are not in possession of material, non-public information. Mussallem plans to enter into similar types of trading plans each year as stock options near their expiration dates in order to spread sales evenly over an extended period of time.

Under the company's stock ownership guidelines, Mussallem is required to own shares of company stock with an aggregate market value equal to six times his base salary. At the conclusion of the plans, Mussallem will still hold shares well in excess of the number required to meet these guidelines. Transactions under these plans will be disclosed publicly through Form 144 and Form 4 filings with the U.S. Securities and Exchange Commission. The Form 4 filings will also be posted on Edwards' investor relations Web site at ir.edwards.com.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at edwards.com.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

# # #


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EDWARDS LIFESCIENCES CORP
12/02 FRIDAY 12/2 INSIDER BUYING REPORT : Ew, dfrg
11/30 EDWARDS LIFESCIENCES : U.S. Patents Awarded to Inventors in Utah (Nov. 30)
11/29 EDWARDS LIFESCIENCES CORP : Blog Coverage Edwards Lifesciences Acquires Valtech;..
11/28 EDWARDS LIFESCIENCES : Israeli Valtech Cardio acquired by Edwards Lifesciences i..
11/28 EDWARDS LIFESCIENCES CORPORATION (NY : EW) Files An 8-K Unregistered Sales of Eq..
11/28 EDWARDS LIFESCIENCES CORP : Unregistered Sale of Equity Securities, Other Events..
11/28 EDWARDS LIFESCIENCES : Enters Into Agreement To Acquire Valtech Cardio
11/24 EDWARDS LIFESCIENCES : Assigned Patent
11/22 EDWARDS LIFESCIENCES' : Trademark Application for "CADENCE" Filed
11/22 EDWARDS LIFESCIENCES : Trademark Application for "OPTISITE" Filed by Edwards Lif..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
12/02 Deals scuppered by U.S. regulatory scrutiny
11/29 European spin-offs and carve-outs
11/15 EXCLUSIVE : EU regulators seen clearing $25 billion Abbott, St Jude deal
11/15 Exclusive - EU regulators seen clearing $25 billion Abbott, St Jude deal
11/02DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
12:25a INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Fldm, amh, spke, infi
12/01 I Believe The Reducer And Tiara Both Work, But Neovasc Is Still A Zero
11/30 Edwards Gets Everything But The Valve
11/29 Edward Lifesciences - Structural Growth Play Starts To Look Appealing, Initit..
11/28 Edwards Lifesciences to buy Israeli cardiac device maker for up to $690M
Advertisement
Financials ($)
Sales 2016 2 979 M
EBIT 2016 822 M
Net income 2016 593 M
Finance 2016 441 M
Yield 2016 -
P/E ratio 2016 30,96
P/E ratio 2017 24,60
EV / Sales 2016 5,83x
EV / Sales 2017 5,14x
Capitalization 17 821 M
More Financials
Chart EDWARDS LIFESCIENCES CORP
Duration : Period :
Edwards Lifesciences Corp Technical Analysis Chart | EW | US28176E1082 | 4-Traders
Full-screen chart
Technical analysis trends EDWARDS LIFESCIEN...
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 121 $
Spread / Average Target 45%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Stanton J. Rowe Chief Scientific Officer & VP-Advanced Technology
John P. McGrath Vice President-Quality, Regulatory & Clinical
John T. Cardis Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
EDWARDS LIFESCIENCES C..5.53%17 821
THERMO FISHER SCIENTIF..-1.23%56 058
DANAHER CORPORATION9.60%53 482
BOSTON SCIENTIFIC CORP..10.95%27 710
PHILIPS15.05%26 897
INTUITIVE SURGICAL, IN..16.57%24 668
More Results